K C Arbour
Overview
Explore the profile of K C Arbour including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
1223
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Di Federico A, Hong L, Elkrief A, Thummalapalli R, Cooper A, Ricciuti B, et al.
Ann Oncol
. 2024 Dec;
36(3):297-308.
PMID: 39637943
Background: Approximately 10% of lung adenocarcinomas (LUADs) have mucinous histology (LUAD), which is associated with a light/absent smoking history and a high prevalence of KRAS mutations. We sought to characterize...
2.
Ricciuti B, Alessi J, Elkrief A, Wang X, Cortellini A, Li Y, et al.
Ann Oncol
. 2022 Jul;
33(10):1029-1040.
PMID: 35872166
Background: Allele-specific KRAS inhibitors are an emerging class of cancer therapies. KRAS-mutant (KRAS) non-small-cell lung cancers (NSCLCs) exhibit heterogeneous outcomes, driven by differences in underlying biology shaped by co-mutations. In...
3.
Luo J, Rizvi H, Preeshagul I, Egger J, Hoyos D, Bandlamudi C, et al.
Ann Oncol
. 2020 Jun;
31(10):1386-1396.
PMID: 32561401
Background: Patients with lung cancers may have disproportionately severe coronavirus disease 2019 (COVID-19) outcomes. Understanding the patient-specific and cancer-specific features that impact the severity of COVID-19 may inform optimal cancer...
4.
Schoenfeld A, Rizvi H, Bandlamudi C, Sauter J, Travis W, Rekhtman N, et al.
Ann Oncol
. 2020 Mar;
31(5):599-608.
PMID: 32178965
Background: Programmed death-ligand 1 (PD-L1) expression is the only FDA-approved biomarker for immune checkpoint inhibitors (ICIs) in patients with lung adenocarcinoma, but sensitivity is modest. Understanding the impact of molecular...
5.
Aguilar E, Ricciuti B, Gainor J, Kehl K, Kravets S, Dahlberg S, et al.
Ann Oncol
. 2019 Aug;
30(10):1653-1659.
PMID: 31435660
Background: In non-small-cell lung cancers with programmed death-ligand 1 (PD-L1) expression on ≥50% of tumor cells, first-line treatment with the PD-1 inhibitor pembrolizumab improves survival compared with platinum-doublet chemotherapy. Whether...
6.
Schoenfeld A, Arbour K, Rizvi H, Iqbal A, Gadgeel S, Girshman J, et al.
Ann Oncol
. 2019 Mar;
30(5):839-844.
PMID: 30847464
Background: Concurrent programmed death-ligand-1 (PD-(L)1) plus osimertinib is associated with severe immune related adverse events (irAE) in epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC). Now that PD-(L)1 inhibitors...
7.
Sabari J, Leonardi G, Shu C, Umeton R, Montecalvo J, Ni A, et al.
Ann Oncol
. 2018 Aug;
29(10):2085-2091.
PMID: 30165371
Background: MET exon 14 alterations are actionable oncogenic drivers. Durable responses to MET inhibitors are observed in patients with advanced MET exon 14-altered lung cancers in prospective trials. In contrast,...
8.
Derosa L, Hellmann M, Spaziano M, Halpenny D, Fidelle M, Rizvi H, et al.
Ann Oncol
. 2018 Apr;
29(6):1437-1444.
PMID: 29617710
Background: The composition of gut microbiota affects antitumor immune responses, preclinical and clinical outcome following immune checkpoint inhibitors (ICI) in cancer. Antibiotics (ATB) alter gut microbiota diversity and composition leading...